Drug Profile
Research programme: aggrecanase inhibitors - Amgen
Latest Information Update: 30 Mar 2010
Price :
$50
*
At a glance
- Originator Alantos Pharmaceuticals
- Class
- Mechanism of Action Aggrecanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 17 Jul 2007 Alantos has been acquired by Amgen
- 23 Aug 2006 Early research in Osteoarthritis in USA (unspecified route)
- 23 Aug 2006 Early research in Rheumatoid arthritis in USA (unspecified route)